罗格列酮对高脂血症大鼠的胰岛素抵抗作用及其机制研究

Effects and mechanisms of rosiglitazone on insulin resistance in rats with hyperlipemia

目的 :研究罗格列酮及格列齐特对高脂血症大鼠胰岛素抵抗的改善作用及其机制。方法 :建立高脂血症大鼠胰岛素抵抗模型 ,并将其分为模型组、罗格列酮组和格列齐特组 ,观察罗格列酮和格列齐特对其糖耐量减退、血清血糖血脂、TNF α、Fins含量、肝细胞TG含量、脂质过氧化和肝肾功能等的影响。结果 :罗格列酮和格列齐特均有可能改善高脂血症致胰岛素抵抗模型病鼠的IGT状态 ,给药 2h后不同程度地降低病鼠FSG及TNF α浓度 (P <0 .0 5 ) ,显著降低病鼠肝组织中TG含量 (P <0 .0 1) ,明显抑制MDA产生 (P <0 .0 1)及增强GSH贮量作用 (P <0 .0 1)。罗格列酮还可降低病鼠高胰岛素水平及Fins浓度 (P <0 .0 1) ,明显降低病鼠BUN和Cr含量 (P <0 .0 5 ) ,提高ISI(P <0 .0 1)及增强SOD活性 (P <0 .0 5 )。结论 :罗格列酮能改善高脂饲养引发的胰岛素抵抗。

AIM : To study the effects and mechanisms of rosiglitazone and gliclazide on insulin resistance in rats induced by high fat diet and hyperlipemia. METHODS : After seven weeks feeding with high fat diet, the rats with insulin resistance were divided into 3 groups: the control group, the rosiglitazone group and the gliclazide group. Insulin and glucose tolerance were tested. Concentrations of tumor necrosis factor α (TNF α) and fasting insulin (Fins) in serum and triacylglycerol (TG), malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione (GSH) were determined in hepatic. RESULTS : The state of impaired glucose tolerance (IGT) was improved, the concentrations of fasting glucose (FSG), TNF α, TG and MDA were decreased ( BX P < 0.05 ), and the deposit of GSH were increased ( P < 0.01 ) by rosiglitazone and gliclazide. The high insulin level and the concentrations of blood (BUN), creatine (Cr) and Fins were decreased and the sensitivity of insulin (ISI) ( P < 0.05 ) was increased by rosiglitazone. CONCLUSION : Rosiglitazone can improve the insulin resistance in rats induced by high fat diet and hyperlipemia.